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Magnesium supplementation is often suggested for restless legs syndrome (RLS) or period limb move-
ment disorder (PLMD) based on anecdotal evidence that it relieves symptoms and because it is also
commonly recommended for leg cramps. We aimed to review all articles reporting the effects of mag-
nesium supplementation on changes in RLS and/or PLMD.
We conducted a systematic search looking for all relevant articles and then two reviewers read all
article titles and abstracts to identify relevant studies. Eligible studies were scored for their quality as
interventional trials.
We found 855 abstracts and 16 of these could not be definitively excluded for not addressing all as-
pects of our research question. Seven full-text articles were unlocatable and one was ineligible which left
eight studies with relevant data. One was a randomised placebo-controlled trial, three were case series
and four were case studies. The RCT did not find a significant treatment effect of magnesium but may
have been underpowered. After quality appraisal and synthesis of the evidence we were unable to make
a conclusion as to the effectiveness of magnesium for RLS/PLMD.
It is not clear whether magnesium helps relieve RLS or PLMD or in which patient groups any benefit
might be seen.
© 2019 Elsevier Ltd. All rights reserved.H/GCP, International Confer-
, International Restless Legs
Movement Disorder; PLMs,
nography; RCT, Randomised
cal Research, 361 Glebe Point
(N.S. Marshall).Introduction
Restless legs syndrome (RLS) is a common condition affecting
5e10% of European and North American adults [1,2]. The four
clinical features required to diagnose RLS were defined by the In-
ternational Restless Legs Study Group [3] as: 1) an urge to move the
N.S. Marshall et al. / Sleep Medicine Reviews 48 (2019) 1012182legs, usually accompanied or caused by uncomfortable and un-
pleasant sensations in the legs, 2) these symptoms begin or worsen
during periods of rest or inactivity such as lying or sitting, 3)
symptoms are partially or totally relieved by movement, such as
walking or stretching, at least as long as the activity continues and
4) symptoms are worse in the evening or night than during the day
or only occur in the evening or night. Periodic Leg Movements in
sleep (PLMs) occur in at least 80% of individuals with RLS [4]. Both
genetic and environmental factors contribute to the prevalence and
severity of RLS, with increased incidence in iron deficiency, preg-
nancy and renal failure [5], leading to the classification of RLS into
primary (idiopathic) or secondary (for instance in renal failure).
Although RLS has been linked to poor sleep [4] and decreased
quality of life, a recent systematic review did not find an increased
risk of mortality with RLS. But there was a suggestion that PLMs (in
particular PLMs with arousals) may be associated with an increased
risk of cardiovascular events and mortality [6]. However, other
recent reviews have found evidence both for and against a car-
diovascular disease association [7,8].
Periodic Limb Movement Disorder (PLMD) occurs in those with
PLMs, but without the symptoms required to diagnose RLS. In
PLMD, PLMs can lead to arousals during sleep and subsequent sleep
disruption. Recent practice parameters [9] for RLS point out that
treatment for both idiopathic RLS and PLMD are essentially similar,
however to date little evidence exists regarding the treatment of
PLMD as a separate entity.
Various pharmacotherapeutic options for symptomatic RLS
exist, although all have notable side effect profiles that may be
unsuitable or unacceptable for many patients. Agents regularly
prescribed include dopamine agonists, ad-ligands and opioid ag-
onists [10,11]. Augmentation is a significant issue with the dopa-
mine agents in particular [12,13] leading to clinical
recommendations of how to treat augmentation and to avoid
choosing them as the first-line therapy option [10]. Iron supple-
mentation is recommended in those with iron depletion [14].
Addressing causative agents (for instance certain anti-depressants
may cause or exacerbate RLS) may also be important. Many pa-
tients may prefer not to use pharmacological therapy and/or use
them intermittently when symptoms require. Treatment options
for milder RLS or alternatives with a more attractive side effect
profile would be welcomed.
There is anecdotal evidence for the use of magnesium supple-
mentation for RLS. We have observed it is often marketed as a
remedy in pharmacies in Australia, New Zealand and Finland for
‘restless sleep’. Magnesium is also widely utilised for nocturnal leg
cramps, which has been proposed to be associated with magne-
sium deficiency, however a recent RCT [15] and an earlier system-
atic review [16] found no therapeutic effect, except possibly a mild
effect in pregnant women [16]. A review in this journal on treat-
ment of RLS in pregnancy found insufficient evidence to make any
conclusion about the effectiveness of magnesium in that patient
group and concluded overall that it should not be used [17]. Despite
magnesium being readily available in a range of food stuffs it is
possible that up to 45% of American adults may have some level of
magnesium deficiency [18]. Despite this we have not found any
theory about how magnesium supplementation could work to
alleviate RLS/PLMD that we find biologically plausible.
We have observed RLS patients recommending magnesium to
each other on the internet. In addition, one of our study team
member's relatives was advised to take magnesium tablets for
PLMD by his sleep physician. There have been some observational
studies in patients reporting that lower magnesium levels were
associated with RLS severity [19,20], however magnesium levels
are to our knowledge not tested in routine clinical practice (and
magnesium levels in blood may not be indicative of magnesiumlevels within the muscle or brain). These observations leave us
asking what the evidence base is for magnesium use in RLS and
how methodologically rigorous those studies are. As such, we aim
to systematically review the health literature to find every study
reporting the effects of magnesium supplementation on the
severity of RLS or PLMD and score the methodological rigour of all
identified studies using a standardised approach for interventional
evidence.
Methods
This systematic review was not preregistered. Our initial
scoping review (YS & NSM) of PubMed yielded only 11 total articles
(The syntax we used in PubMed was: (magnesium or magmin) and
(“restless leg*” or “periodic limb*” or “willis-ekbom” or “willis
ekbom” or “periodic leg*”) and no limits were applied. This sug-
gested to us that we maintain a broad and open search strategy to
help guarantee all pertinent evidence was collected. Because we
failed to locate a single randomised controlled trial at this point we
also expected that the evidence synthesis would need to be built on
lower quality evidence. Our scoping review also indicated that we
would be unlikely to be able to meta-analyse the results due to the
paucity of combinable studies.
Two investigators (YS & NSM) developed the research question
(see Appendix 1) and then designed search syntax in conjunction
with the librarian team (JMC& IR) tomaximise search yield across a
number of databases selected specifically to attempt to find any
article published on the topic at any time (see Appendix 2 for full
search syntax).
We searched for clinical intervention studies testing oral or
other methods of magnesium supplement administration in pa-
tients with RLS, or PLMD, or both. We included studies with pa-
tients suffering from either primary or secondary restless legs
syndrome (for instance, RLS secondary to kidney disease [but not
including patients receiving dialysis] or pregnancy). These patients
were chosen because they are more likely to be within the clinical
practice of a sleep physician. We included any dose of magnesium
other than homeopathic and we included any comparator to
magnesium. Any longitudinal clinical study design, including case
series or case studies, was accepted. There were no restrictions on
length of follow up, or publication language, or date of publication.
We searched 19 different databases, including Web of Science,
Medline, Scopus and CINAHL between the 28th August and the 5th
October 2018 (see Appendix 2).
Every title and abstract was read by two independent reviewers
(NSM RK CB JLC TL MC) who systematically assessed, in this order,
whether the title and abstract did not include 1. original data, 2. a
clearly delineated group of patients presenting with restless legs
syndrome, or periodic limb movement disorder, or both, 3. mag-
nesium supplementation, 4. a measure of change in the clinical
severity of RLS/PLMD in conjunctionwith, 5. any longitudinal study
design. If the abstract could not be definitively excluded (such as
when there was no abstract and the title was insufficiently
descriptive), a full text review was undertaken and the same
criteria applied to remove articles not reporting data on the
question.
Abstracts or articles written in Spanish or German were
reviewed by members of our review team who were native
speakers or studied those languages through to the end of high
school or at a university level (RK TL RWMC JLC). Studies published
in any Scandinavian language were reviewed by a team member
(TL) proficient in those languages and via Google translate.
Inclusion and exclusion criteria were applied at the full text
screening stage unless obviously reported in the abstract. Inclu-
sion: Community dwelling patients rather than hospitalised
Number of ar cles 
iden fied from 
databases n= 873
Number of ar cles 
iden fied from other 
sources n= 1
Number of abstracts reviewed a er duplicates removed 
n= 855
Did not contain original data 305
Not in Restless legs or Periodic Limb movement 495
Not supplemen ng magnesium 38
Did not measure a change in disease outcome 1
Not a longitudinal study 0
Full text Screening 16
Non-locatable 7
Rejected on Inc/Excl 1
Studies included in review n= 8
1 Randomised controlled trial
Fig. 1. Flow chart of the study selection procedure.
N.S. Marshall et al. / Sleep Medicine Reviews 48 (2019) 101218 3populations (such as in intensive care unit or in defined specialist
clinical populations such as dialysis patients). PLMD or RLS could
be diagnosed by clinical or laboratory methods, or both. There was
no limit on the length of intervention (i.e., we would review a
single dose study) before the outcome was measured and there
was no limit on the method of measuring change in disease
severity. Pregnancy was not an exclusion. We did not restrict by
publication type or venue (peer-reviewed or non peer-reviewed).
Exclusion: In vitro or animal studies (i.e., not biological samples
taken from an RLS patient or patients and then treated with
magnesium in vitro).
Data were extracted and tabulated from all eligible studies by at
least two investigators (NSM RW JLC). We did not contact authors
for clarification of unreported data. We did contact an author of an
abstract [21] reporting a pertinent randomised controlled trial
whenwewere unable to locate the corresponding full length article
in order to ascertain whether there was a full length published or
unpublished report available (for instance, a clinical trial report or
thesis [22]).
Quality review
We scored the quality of the studies based on amodified version
of the Cochrane risk of bias tool for interventional studies [23]. We
searched for evidence of randomisation via a computerised
method, secure concealment of that random list from the clinical
investigators enrolling patients, blinding of the investigators and
patients from the intervention being received, intention to treat
analyses and finally that the trial reported the outcomes it was pre-
registered to collect relevant to the RLS/PLMD outcome. When this
was done well and properly described, we gave a green tick (indi-
cating a low risk of bias), when it was unclear but may have been
done well, we gave an orange ‘?’ (indicating the possibility of bias)
and when not done, we gave a red X indicating a serious risk of bias
(see Table 2).
Results
Our search of all databases yielded 855 abstracts after duplicates
were removed. The results of our sorting algorithm can be seen in
Fig. 1. 305 articles were rejected for not having original data re-
ported in them; 495 did not have a clear group of RLS/PLMD pre-
senting patients; 38 did not have magnesium supplementation and
one did not report a change in RLS/PLMD leaving 16 articles that
required full text review because we were unable to definitively
exclude them based on their title and abstract alone (see Fig.1). One
article was a thesis in Spanish that was rejected at full text review
because it did not contain patients with RLS/PLMD [24]. A case
series described in a neurology journal was also not retrievable but
appeared to have a case of RLS described in it [25]. We were unable
to locate an abstract or full text to assess three articles about RLS/
PLMD in natural health publications properly [26e28]. Another
potentially relevant article in German had no abstract and wewere
unable to locate any text for it [29]. An article in Hungarian had
neither an abstract or full text we could locate [30]. A final (but
likely irrelevant based on its title) article was in an issue that was
missing from our library [31]. This left eight articles with relevant
data that are listed in Table 1. The heterogeneity in the study de-
signs and the incompleteness of reporting meant that we were not
prepared to meta-analyse the results which would create a
misleading summary estimate. We included a case study in Polish
based on its English abstract but were unable to review its full text
completely [32].
There was one randomised placebo controlled trial [22] which
we located because it was published as an abstract [21]. Neither thePSG measured severity of PLMS or the questionnaire based mea-
sures of RLS severity or clinical global impression (CGI) were
significantly improved by magnesium compared to placebo.
Qualitative synthesis of the non-randomised study findings
would generally indicate that RLS/PLMs tended to improve in
conjunction with magnesium e however because of the biased
nature of these study designs we cannot tell if this is really caused
by magnesium (see Table 2). The studies were case series or case
reports meaning that there are almost no high quality studies that
address the effectiveness of magnesium alone for RLS or PLMD.
They lack control groups and magnesium is often used in
conjunction with other agents. So establishing causality is
impossible.
The results of the quality appraisal are in Table 2. The RCT [22]
used randomisation but it was not clear how the sequence was
generated or how it was kept secret from the investigators (allo-
cation concealment). We judged that the techniques used to
maintain blinding were unlikely to have introduced bias and that
there was minimal data loss after randomisation that would have
damaged the assumption of intention-to-treat analyses. All other
studies were case studies or case series and therefore did not
employ any of the biasminimising techniques used in RCTs. None of
the included studies were pre-registered, making it unclear
whether reporting bias may have existed (the sole RCT was un-
dertaken before mandatory registration came into effect).
Discussion
There is very little high quality evidence testing the hypothesis
thatmagnesium supplementation is effective in treating RLS/PLMD.
Apart from a single parallel armed randomised controlled trial
Table 1
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and four case reports (see Table 1). The uncontrolled studies did not
have control arms and frequently reported magnesium use in
conjunction with other agents, meaning that causality cannot be
reliably ascertained in a conditionwhere placebo effects are known
to be large [36]. They also suffer from a number of well-known
biases that preclude making strong interventional conclusions
(see Table 2). However, this absence of evidence does not rule out
the possibility that magnesium supplementation does have a
meaningful therapeutic effect on RLS or PLMS.
The single RCT we found [22] did not find that oral magnesium
(364.8 mg daily) relieved RLS. But this could be a false negative due
to underpowering and some inequality in the severity of the con-
dition in the two treatment groups at baseline. The baselinemedian
serum magnesium levels in the trial patients (0.79 mmol/l in
treatment group and 0.81 mmol/l in the placebo group) were close
to a recently reported German general population average
(0.82 mmol/l) [20]. In addition serum magnesium did not signifi-
cantly increase in the intervention group and the groups did not
differ significantly after treatment [22]. Together these factors may
have inhibited the detection of a true beneficial effect of magne-
sium. Diarrhea was the major reported side-effect of magnesium
supplementation in this trial with seven reported incidents in pa-
tients in the active arm (5 mild and two severe) versus none in the
placebo treated patients [22].
Readers of this field may also be interested in an RCT protocol
we found that may report data in the future
[IRCT2017070134806N1]. It compares the effects of magnesium to
vitamin B6 supplementation in patients also receiving pramipexole.
However, this single-blinded trial is only enrolling 25 patients in
each of three arms and was due to complete recruitment by March
2018 (https://en.irct.ir/trial/26502).
Our search was not designed to detect studies exploring the
association between restless legs syndrome and magnesium levels.
However, we did locate observational studies reporting inconsis-
tent associations between magnesium levels and RLS [37,38].
Immediately after our search date Szentkiralyi and colleagues [20]
published a much larger population-based study of PLMS
(n ¼ 1107). They report a very small univariate difference in serum
magnesium levels between people with and without PLMS (PLMIndex >15/hr; 0.81 vs 0.82 mmol/L, p ¼ 0.01). However, this dif-
ference is too small to present a viable clinical trial target in a broad
spectrum of patients. This observational study also brings into
doubt the likelihood that magnesium could be an effective treat-
ment in a broad spectrum of RLS/PLMS patients because the
afflicted cases do not have magnesium deficiency. It remains
possible that in susceptible patients with low magnesium and RLS,
supplementation with magnesium might be effective, but such an
approach must be tested in a properly powered trial with robust
design.
Magnesium supplementation potentially represents a cheap
and relatively safe therapeutic option for sufferers of RLS. However,
our systematic review located no studies that definitely demon-
strate whether magnesium is efficacious or not and the observa-
tional studies have not demonstrated that a treatable magnesium
deficiency exists.
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Practice Points
 There is no evidence supporting the use of magnesium
supplementation in RLS, despite its anecdotal use. We
don't know whether any formulation at any dose may or
may not be effective.
 Patients may report significant clinical benefit from taking
magnesium. Given the current evidence base we would
not tell patients that the supplement is in fact not working
for them.
 Dietary supplements are generally safe but we don't know
what the specific side-effect profile of magnesium in RLS
patients is. The sole RCT indicates a clinically significant
problem with diarrhea.
 The role of magnesium in the pathogenesis of RLS/PLMS
in any subset of patients has yet to be demonstrated.
 We do not recommend routine testing of magnesium
levels in RLS patients to guide any clinical decisions.
Research Agenda
 It is not clear whether magnesium is either an effective or
ineffective therapy for RLS/PLMD because of the paucity
of published clinical studies. The apparent widespread
use of this remedy leads to recommend that adequately
powered double blind studies be conducted. We would
also recommend that safety data be collected in these
trials in compliance with ICH/GCP.
 This is particularly important when patient reports of their
RLS severity appear to be subject to significant placebo
effects [36].
 We also think it worth noting that the best quality obser-
vational study to date has not clearly indicated that RLS is
associated with lower circulating magnesium levels [20].
Future trial investigators may want to select or stratify
patients based on their baseline magnesium levels.
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